(French) : Découverte d’une nouvelle cible thérapeutique chez E. coli

These contents could be interesting :

COVID-19: Infection-Vaccination is the Most Protective Combination Against Reinfection

A large part of the population has developed immunity against SARS-CoV-2 following infection, vaccination – or both. In addition, some infected patients enjoy "hybrid" immunity when they are vaccinated....

Hepcidin, iron hormone in the skin: a new target in the treatment of psoriasis?

Psoriasis is a chronic inflammatory disease characterised by the rapid and excessive multiplication of skin cells. Although research is progressing and certain treatments are already able to improve the....

Medias

Researcher Contact

Eric Oswald Centre de Physiopathologie de Toulouse Purpan (Inra, Inserm, CNRS, Université Toulouse III - Paul Sabatier) Département scientifique « Microbiologie et chaîne alimentaire » 05 62 74 45 43 revp.bfjnyq@vafrez.sePatricia Martin Centre de Physiopathologie de Toulouse Purpan (Inra, Inserm, CNRS, Université Toulouse III - Paul Sabatier) Département scientifique « Microbiologie et chaîne alimentaire » 05 31 54 79 53 cngevpvn.znegva@vafrez.se

Sources

Interplay Between Siderophores and Colibactin Genotoxin Biosynthetic Pathways in Escherichia coli.Patricia Martin, Ingrid Marcq, Giuseppe Magistro, Marie Penary, Christophe Garcie, Delphine Payros, Michèle Boury, Maïwenn Olier, Jean-Philippe Nougayrède, Marc Audebert, Christian Chalut, Sören Schubert, Eric Oswald.PLoS Pathogens, 11 juillet 2013.